Aktis Oncology (AKTS) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx is the larger company by market cap ($1.01 billion vs $986.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | MGTX |
|---|---|---|
| Share price | $17.74 | $10.50 |
| Market cap | $986.69M | $1.01B |
| 1-day change | -1.44% | -2.96% |
| YTD return | — | +36.10% |
| 1-year return | — | +27.44% |
| 5-year return | — | -24.23% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-1.70 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $15.35 |
| 52-week low | $14.72 | $6.62 |
| Distance from 52-week high | -48.11% | -31.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.49% | +164.29% |
| Average volume | 364.04K | 797.37K |
| Shares outstanding | 53.75M | 96.04M |
| Employees | 79 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
AKTS vs MGTX FAQ
Which is bigger, Aktis Oncology or MeiraGTx?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.01B compared with $986.69M for Aktis Oncology (AKTS).
Are Aktis Oncology and MeiraGTx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aktis Oncology and Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx.